Hawaii will receive $583,328 as part of a $40.75 million settlement between pharmaceutical company GlaxoSmithKline and 37 states and the District of Columbia over the distribution of prescription drugs manufactured at a Puerto Rico facility, the state Office of Consumer Protection said Thursday.

The Hawaii share will go into a special fund for consumer protection.

The settlement is in response to claims by the 38 states that drugs produced by GSK subsidiary SB Pharmco Puerto Rico were not sterilized and therefore adulterated. Other claims alleged the products contained dosages different than what was indicated on the packaging.

SB Pharmco is no longer in business and the drugs it produced between 2001 and 2004 have already been taken off the shelves or have expired. They include: Kytril, used to prevent nausea and vomiting caused by cancer chemotherapy and radiation therapy; Bactroban, and antibiotic ointment used to treat skin infections; Paxil CR, a controlled release formulation of the antidepressant drug Paxil; and Avandamet, a combination Type II diabetes drug.

The state Office of Consumer Protection said there were no reports of complications from the use of the above mentioned drugs in Hawaii.